Dr. Kenneth P. Olive is a tenured Associate Professor of Medicine at Columbia University. He leads a translational research program devoted to developing new treatments for pancreatic cancer and bringing advances from the laboratory to the clinic. Dr. Olive performed his doctoral studies in cancer genetics in the laboratory of Dr. Tyler Jacks at MIT where he developed a widely-used mouse model of lung adenocarcinoma and made seminal advances in understanding the hereditary tumor predisposition Li-Fraumeni Syndrome. Subsequently, Dr. Olive joined the laboratory of Dr. David Tuveson at UPenn and the University of Cambridge in England, where he built a translational research facility for studying new drugs in genetically engineered mouse models of pancreatic cancer. Dr. Olive’s postdoctoral research on chemoresistance led to the understanding that pancreatic tumors have a sparse and inefficient vasculature that limits the delivery of drugs to tumor tissues. In 2010, began his independent career at Columbia University. He has published landmark papers on pancreatic tumor metabolism, the role of the tumor stroma, and most recently on the use of RAS inhibitors in the treatment of pancreatic cancer. These efforts and others have led to multiple clinical trials for pancreatic cancer patients at Columbia/NY Presbyterian Hospital and nationally.